Stämm Biotech
Verona Llamazares Vegh's work experience began in 2007 at Shell Gas, where they started as a Cuentas a Pagar and later became a Controller. Their responsibilities included analyzing and registering supplier invoices, reconciling accounts, and providing customer service to suppliers. In 2016, they became the Responsable de Compras y Contrataciones at Shell Gas, where they coordinated purchasing activities, managed accounts payable, and was responsible for budget control and process improvement. In 2019, they joined Stämm Biotech as the Administration & Finance Department Leader.
Verona Llamazares Vegh pursued a Licenciatura degree in Economic Development at the Universidad Nacional de Quilmes, where they studied until 2020.
This person is not in any teams
This person is not in any offices
Stämm Biotech
Stämm is a biotechnology company dedicated to making biomanufacturing easy, scalable, and repeatable. We have developed the first methodology for continuous industrial production of biologics and cell therapies leveraging microfluidics and 3D printing. In 2020, the total volume of anthropogenic mass matched the total amount of biomass globally, which means it matched everything that is alive on the planet. We can only expect that this number keeps increasing since it's key to solving humanity's systemic challenges. But we have to make sure that conquering the great challenges of humanity doesn’t extinguish the planet’s capacity to sustain life. The current way of biomanufacturing has provided humanity with innumerable solutions. Bioprocessing is the most efficient way to align human advancement with a thriving nature. In order to prevent nature from perishing, we aim to put it at the center of all human activities by incorporating its knowledge system within the process of achieving humanity's prosperity. Founded in 2016, Stämm mimics nature’s use of laminar flow to down-size a whole biotech facility into an all-in-one, plug & play desktop unit. Our focus is to decentralize bioprocesses and democratize access to biotechnology products, thus freeing our partners to focus on the disruptive discoveries that make an impact on people’s life.